focus -WSS

focus

author：entertainment 2025-09-27 17:03:20 - browse：4863

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Long Covid research funding gets a major boost from NIH

hotspot

WSS

Mexico finds 491 migrants being held at vacant lot, almost all are from Guatemala

Tuberculosis patients need more than just free medication

Sage considers ways to reduce costs following FDA rejection

Abbott's new heart device gets FDA advisory panel nod

Trump used to be more articulate. What could explain the change?

How CRISPR works, explained in two minutes

focus

focus

leisure time

Moonlake's readout produced a cash windfall. Risks remain

Sage considers ways to reduce costs following FDA rejection

Walensky prepares to leave CDC — and Congress — behind

Paxlovid rebound happens. Why and to whom are still a mystery

United colonoscopy coverage change 'may cost lives,' doctors say

AMAs digital advisors table RPM coding reform proposal, again

DIEP, the 'gold standard' of breast reconstruction, is under threat

Having children helps parents live longer, especially after age 80

Hepatitis C has a cure — but many Americans still lack access to it

With heat waves through August, officials warn of health risks

leisure time

Doctors on social media are being harassed and cyberbullied

Having children helps parents live longer, especially after age 80

Abbott's new heart device gets FDA advisory panel nod

Ebola vaccine can save some who are already sick, per new study

Bernie Sanders gets little from pharma CEOs on drug prices

Judge in Trump's classified documents case questions use of out

knowledge

hotspot

focus

focus